Assessing patient fitness involves more than evaluating chronological age, noted Brandon Blue, MD, of the Moffitt Cancer ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

NICE has said Celgene's Vidaza (azacitidine) should not be funded by the National Health Service, estimating it costs the health system more than ten times as much as estimated by the manufacturer.

Celgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws nearer. Its latest – with Immatics – bolsters its immuno-oncology business and ...

R&D Expenses: Research and development expenses for the third quarter of 2024 were $1.0 million, compared to $1.9 million for ...

The market’s momentum is fueled by a concerted effort towards the development of innovative treatments for hematologic malignancies. Advances in drug discovery, coupled with regulatory approvals for ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...